DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

Information source: University Hospital, Basel, Switzerland
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Non Alcoholic Fatty Liver Disease; Non Alcoholic Steatohepatitis

Intervention: Oral glucose tolerance test (Other)

Phase: N/A

Status: Completed

Sponsored by: University Hospital, Basel, Switzerland

Official(s) and/or principal investigator(s):
Christoph Beglinger, MD, Principal Investigator, Affiliation: University Hospital Basel, Division of Gastroenterology and Hepatology


The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM. Insulin resistance is a pathophysiologic hallmark of non-alcoholic fatty liver disease (NAFLD). The incretin effect in patients with NAFLD has not been studied. The aim of this study is to quantify GLP-1 secretion in response to oral glucose tolerance test (oGTT) in patients with NAFLD compared to healthy controls. The results of this study will expand the knowledge of the pathophysiology of NAFLD and serve as a rational for potential future treatment strategies.

Clinical Details

Official title: Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

Study design: Observational Model: Case Control, Time Perspective: Prospective

Primary outcome: Glucagon-like Peptide 1 (GLP-1) secretion in response to oGTT

Secondary outcome: Insulin secretion and glucose curves in response to oGTT

Detailed description: Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin responses to oral glucose challenge


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Biopsy proven NAFLD or NASH

Exclusion Criteria:

- additional concomitants liver disease

- T2DM

- alcohol consumption >40g/d for male subjects and >20g/d for female subjects

Locations and Contacts

University Hospital Basel, Division of Gastroenterology and Hepatology, Basel, Switzerland
Additional Information

Starting date: January 2011
Last updated: August 24, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017